300 related articles for article (PubMed ID: 18703472)
1. The effects of tibolone in older postmenopausal women.
Cummings SR; Ettinger B; Delmas PD; Kenemans P; Stathopoulos V; Verweij P; Mol-Arts M; Kloosterboer L; Mosca L; Christiansen C; Bilezikian J; Kerzberg EM; Johnson S; Zanchetta J; Grobbee DE; Seifert W; Eastell R;
N Engl J Med; 2008 Aug; 359(7):697-708. PubMed ID: 18703472
[TBL] [Abstract][Full Text] [Related]
2. Short-term and long-term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; Wilkinson J; Basevi V; Marata AM; Magrini N; D'Amico R; Bassi C; Maestri E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD008536. PubMed ID: 27733017
[TBL] [Abstract][Full Text] [Related]
3. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
4. Tibolone and the promise of ideal hormone-replacement therapy.
El-Hajj Fuleihan G
N Engl J Med; 2008 Aug; 359(7):753-5. PubMed ID: 18703480
[No Abstract] [Full Text] [Related]
5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma of the endometrium in patients treated with tibolone.
Yazigi R; Sahid S; Contreras L; Rodriguez T
Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
[TBL] [Abstract][Full Text] [Related]
7. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
Reginster JY
J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
9. Muscle strength and tibolone: a randomised, double-blind, placebo-controlled trial.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
BJOG; 2002 Jan; 109(1):77-84. PubMed ID: 11845814
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
[TBL] [Abstract][Full Text] [Related]
11. Tibolone: the way to beat many a postmenopausal ailments.
Lazovic G; Radivojevic U; Marinkovic J
Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Kenemans P; Bundred NJ; Foidart JM; Kubista E; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Yip CH; Egberts J; Mol-Arts M; Mulder R; van Os S; Beckmann MW;
Lancet Oncol; 2009 Feb; 10(2):135-46. PubMed ID: 19167925
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
[TBL] [Abstract][Full Text] [Related]
16. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J
Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493
[TBL] [Abstract][Full Text] [Related]
17. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
Biglia N; Maffei S; Lello S; Nappi RE
Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
[TBL] [Abstract][Full Text] [Related]
18. Tibolone in older postmenopausal women.
Chlebowski RT; Prentice R
N Engl J Med; 2008 Nov; 359(20):2172-3; author reply 2173. PubMed ID: 19005202
[No Abstract] [Full Text] [Related]
19. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
[TBL] [Abstract][Full Text] [Related]
20. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
Lundström E; Christow A; Kersemaekers W; Svane G; Azavedo E; Söderqvist G; Mol-Arts M; Barkfeldt J; von Schoultz B
Am J Obstet Gynecol; 2002 Apr; 186(4):717-22. PubMed ID: 11967497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
